IL248979B - Syntac polypeptides and their uses - Google Patents

Syntac polypeptides and their uses

Info

Publication number
IL248979B
IL248979B IL248979A IL24897916A IL248979B IL 248979 B IL248979 B IL 248979B IL 248979 A IL248979 A IL 248979A IL 24897916 A IL24897916 A IL 24897916A IL 248979 B IL248979 B IL 248979B
Authority
IL
Israel
Prior art keywords
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
IL248979A
Other languages
English (en)
Hebrew (he)
Other versions
IL248979A0 (en
Original Assignee
Albert Einstein College Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine Inc filed Critical Albert Einstein College Medicine Inc
Publication of IL248979A0 publication Critical patent/IL248979A0/en
Publication of IL248979B publication Critical patent/IL248979B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL248979A 2014-06-18 2016-11-15 Syntac polypeptides and their uses IL248979B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
IL248979A0 IL248979A0 (en) 2017-01-31
IL248979B true IL248979B (en) 2020-06-30

Family

ID=54936224

Family Applications (3)

Application Number Title Priority Date Filing Date
IL248979A IL248979B (en) 2014-06-18 2016-11-15 Syntac polypeptides and their uses
IL266570A IL266570B (en) 2014-06-18 2019-05-12 Syntac polypeptides and their uses
IL275307A IL275307B (en) 2014-06-18 2020-06-11 Syntac polypeptides and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL266570A IL266570B (en) 2014-06-18 2019-05-12 Syntac polypeptides and their uses
IL275307A IL275307B (en) 2014-06-18 2020-06-11 Syntac polypeptides and their uses

Country Status (15)

Country Link
US (5) US20170058015A1 (OSRAM)
EP (3) EP3483179B1 (OSRAM)
JP (4) JP6652932B2 (OSRAM)
KR (1) KR102252119B1 (OSRAM)
CN (3) CN113248624B (OSRAM)
AU (3) AU2015277460B2 (OSRAM)
DK (2) DK3157552T3 (OSRAM)
ES (2) ES2767259T3 (OSRAM)
HU (2) HUE048076T2 (OSRAM)
IL (3) IL248979B (OSRAM)
PL (2) PL3480213T3 (OSRAM)
PT (2) PT3480213T (OSRAM)
SG (2) SG11201609876TA (OSRAM)
TW (3) TWI795740B (OSRAM)
WO (1) WO2015195531A2 (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
JP2019516665A (ja) * 2016-03-02 2019-06-20 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
JP7372036B2 (ja) * 2016-03-03 2023-10-31 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
BR112018073606A2 (pt) * 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
WO2017201131A1 (en) * 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
WO2018119114A1 (en) * 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) * 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
US11407806B2 (en) * 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
CN110869494B (zh) * 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
US11708418B2 (en) * 2017-08-10 2023-07-25 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
JP2021500855A (ja) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド 抗原提示ポリペプチドおよびその使用方法
EA202090471A1 (ru) * 2017-09-07 2020-06-10 Кью Биофарма, Инк. Модулирующие т-клетки мультимерные полипептиды и способы их применения
WO2019106592A2 (en) * 2017-11-30 2019-06-06 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
CA3123102A1 (en) * 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2020132138A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
WO2020181062A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2020282736B2 (en) * 2019-05-29 2025-10-30 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
AU2020348373A1 (en) * 2019-09-20 2022-02-24 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
AU2020370292A1 (en) * 2019-10-23 2022-03-03 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US20230076204A1 (en) * 2020-02-18 2023-03-09 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
EP4106790A4 (en) * 2020-02-21 2024-02-21 3T Biosciences, Inc. YEAST DISPLAY LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE
US20230126784A1 (en) * 2020-03-06 2023-04-27 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
JP2023525822A (ja) * 2020-05-12 2023-06-19 エルジー・ケム・リミテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
WO2022197970A2 (en) * 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
AU2022253266A1 (en) * 2021-04-07 2023-11-23 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
JP2024519500A (ja) * 2021-05-07 2024-05-14 インスティチュート フォー システムズ バイオロジー 単鎖三量体ｍｈｃクラスｉ核酸およびタンパク質ならびに使用方法
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
WO2023023641A2 (en) * 2021-08-20 2023-02-23 3T Biosciences, Inc. Peptide-hla-b*35 libraries, associated compositions, and associated methods of use
US20250059254A1 (en) * 2022-01-03 2025-02-20 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
US20250271443A1 (en) * 2022-04-21 2025-08-28 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
WO2002072631A2 (en) * 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
JP5843357B2 (ja) * 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
WO2014083004A1 (en) 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
EP3737689A4 (en) * 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF

Also Published As

Publication number Publication date
JP6652680B2 (ja) 2020-02-26
JP6995151B2 (ja) 2022-02-21
US20200377569A1 (en) 2020-12-03
HUE048076T2 (hu) 2020-07-28
JP2022046544A (ja) 2022-03-23
SG11201609876TA (en) 2017-01-27
JP2020022491A (ja) 2020-02-13
PL3480213T3 (pl) 2020-05-18
IL266570A (en) 2019-07-31
PT3480213T (pt) 2020-02-04
SG10202006338UA (en) 2020-08-28
IL266570B (en) 2020-06-30
EP3480213B1 (en) 2019-11-13
CN113248624B (zh) 2025-02-07
AU2015277460B2 (en) 2020-10-08
TWI795740B (zh) 2023-03-11
EP3157552B1 (en) 2019-10-23
JP7331075B2 (ja) 2023-08-22
CN113248623A (zh) 2021-08-13
AU2015277460A1 (en) 2016-11-24
CN106456733A (zh) 2017-02-22
TW201613966A (en) 2016-04-16
AU2019203442B2 (en) 2021-04-08
DK3157552T3 (da) 2020-01-13
AU2021204594A1 (en) 2021-07-29
TW202124435A (zh) 2021-07-01
EP3157552A2 (en) 2017-04-26
IL275307A (en) 2020-07-30
TW201946933A (zh) 2019-12-16
TWI696633B (zh) 2020-06-21
WO2015195531A3 (en) 2016-02-25
US20170058015A1 (en) 2017-03-02
PL3157552T3 (pl) 2020-05-18
TWI722576B (zh) 2021-03-21
JP6652932B2 (ja) 2020-02-26
US20210238254A1 (en) 2021-08-05
CA2947489A1 (en) 2015-12-23
EP3480213A1 (en) 2019-05-08
EP3157552A4 (en) 2017-11-22
WO2015195531A2 (en) 2015-12-23
PT3157552T (pt) 2020-01-22
EP3483179A1 (en) 2019-05-15
DK3480213T3 (da) 2020-02-17
HUE047255T2 (hu) 2020-04-28
US20210047384A1 (en) 2021-02-18
JP2020072733A (ja) 2020-05-14
KR102252119B1 (ko) 2021-05-17
KR20170030484A (ko) 2017-03-17
US20180282392A1 (en) 2018-10-04
ES2770330T3 (es) 2020-07-01
AU2019203442A1 (en) 2019-06-06
IL248979A0 (en) 2017-01-31
CN113248624A (zh) 2021-08-13
BR112016027897A2 (pt) 2017-10-24
EP3483179B1 (en) 2020-09-16
AU2021204594B2 (en) 2024-05-09
IL275307B (en) 2022-03-01
CN106456733B (zh) 2021-03-16
JP2017519491A (ja) 2017-07-20
ES2767259T3 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
SG11201609274SA (en) Novel specific-binding polypeptides and uses thereof
IL250502B (en) New polypeptides
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
GB201410031D0 (en) Polypeptides and uses thereof
IL254241A0 (en) Etv2 and its uses
IL251289B (en) New peptide derivatives and their use
SG11201610918RA (en) Peptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201401973D0 (en) Antibody polypeptides and uses thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201403024D0 (en) Polypeptides
GB201407419D0 (en) Conductive materials and uses thereof
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed